ID   FM88
AC   CVCL_9679
SY   FM-88
DR   cancercelllines; CVCL_9679
DR   Cosmic; 851422
DR   Cosmic; 874442
DR   Cosmic; 1047681
DR   Cosmic; 1181745
DR   Cosmic; 1221591
DR   Cosmic; 2163780
DR   ECACC; 13012421
DR   ESTDAB; ESTDAB-029
DR   GEO; GSM156049
DR   IARC_TP53; 26107
DR   Progenetix; CVCL_9679
DR   Wikidata; Q54835070
RX   PubMed=9288767;
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=23851445;
CC   HLA typing: A*02:01,02:05; B*27:04,49:01; C*01:02,07:01:01; DPB1*04:01; DQB1*03:02:01,05:01:01; DRB1*01:01,04:01:01 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Gly127Glu (c.380G>A); ClinVar=VCV000428225; Zygosity=Unspecified (PubMed=9288767; PubMed=17260012; PubMed=23851445).
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
ST   Source(s): ECACC=13012421; ESTDAB=ESTDAB-029
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 10,12
ST   D16S539: 9,13
ST   D3S1358: 15,16
ST   D5S818: 11
ST   D7S820: 12
ST   FGA: 21,23
ST   TH01: 7,9
ST   TPOX: 9,11
ST   vWA: 16,19
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 23
//
RX   PubMed=9288767;
RA   Guldberg P., thor Straten P., Birck A., Ahrenkiel V., Kirkin A.F.,
RA   Zeuthen J.;
RT   "Disruption of the MMAC1/PTEN gene by deletion or mutation is a
RT   frequent event in malignant melanoma.";
RL   Cancer Res. 57:3660-3663(1997).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello Osuna F., Dodi I.A.,
RA   Lopez-Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//